Clinical Trial Update: Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of hormonal ablation, imatinib mesylate, and docetaxel for prostate cancer has completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-08-04